Table 3.

Results From Univariate and Multivariate Analysis of Predictors of Mortality, From Cox’s Proportional Hazard Regression Models

Variable	Univariate models		Multivariate models
	HR (95% CI)	P value	HR (95% CI)	P value
Age
Linear (1-year increase)	1.06 (1.03–1.10)	<.0001
60–70 vs ≤60 years	2.58 (1.12–5.94)	.0255	2.20 (0.94–5.13)	.068
>70 vs ≤60 years	5.49 (2.42–12.48)	<.0001	4.16 (1.78–9.73)	.001
Sex (male vs female)	1.39 (0.71–2.73)	.3438
Indication for LT
Decompensated cirrhosis	1.11 (0.61–2.00)	.736
Hepatocellular carcinoma	1.25 (0.67–2.34)	.4846
Other	0.63 (0.25–1.61)	.3362
Time between LT and COVID-19 symptoms (1-year increase)	1.05 (1.01–1.09)	.0054
Body mass index (1-unit increase)	1.00 (0.94–1.07)	.9936
Comorbidities
Diabetes	1.98 (1.11–3.54)	.0212
Hypertension	1.76 (0.98–3.17)	.0584
Chronic lung disease	0.55 (0.17–1.76)	.3126
Chronic kidney diseasea	2.20 (1.19–4.08)	.0123	1.72 (0.92–3.22)	.0912
Coronary artery disease	1.37 (0.49–3.81)	.5518
Other	1.71 (0.89–3.31)	.1095
Comorbidities, n
1 vs 0	3.54 (1.02–12.33)	.0468
≥2 vs 0	5.63 (1.72–18.50)	.0044
Smoking (yes vs no)	1.62 (0.72–3.63)	.241
Type of immunosuppressant
CsA vs all other	2.29 (1.13–4.60)	.0209
TAC vs all other	0.43 (0.24–0.77)	.0042	0.55 (0.31–0.99)	.0472
MMF vs all other	1.30 (0.73–2.33)	.3704
mTOR inhibitors vs all other	1.37 (0.66–2.84)	.3969
Treatment with ACE inhibitors or angiotensin II receptor antagonists (yes vs no)	1.92 (1.06–3.49)	.0328
Country
Spain vs Other	1.52 (0.67–3.48)	.3178
Italy vs Other	1.34 (0.54–3.34)	.5253
France vs Other	1.48 (0.55–3.94)	.4355
Center recruiting more than 9 patients vs other centers	1.47 (0.82–2.65)	.1993

NOTE. Bold values are statistically significant (P < .05).

ACE, angiotensin converting enzyme; CT, computed tomography; HR, hazard ratio; mTOR, mammalian target of rapamycin.

^aPlasma creatinine >2 mg/dL.